Ann: Admedus to host Investor Webinar, page-86

Quick notes from the Q&A section;

Share consolidation - why? Several reasons;
i) Request came from some shareholders
ii) Very important we not be seen as penny stock
iii) Curbing intra-day trading
iv) Could bring AISC costs down

Cash burn/goals to profitability;
i) Goal is to make AHZ profitable!
ii) 16.7M in cash at the moment
iii) Have received an R&D rebate, and expecting others
iv) Building a franchise around regen tissue, infusion lines, etc.
v) Looking internally to manage our capital
vi) Looking to 'get value' out of our immunotherapies 'as we go forward'

How are Cardiocel sales going?
110 centres globally
Looking to Africa to increase number of centres
Becoming preferred scaffold in the market
Heart valve study is very important; significant market
Seeking new territories/partnerships
Regenerative tissue

HSV-2 update? Vaccine technology in general
Recruitment almost complete - almost have the required 40
Will continue to enrol until 40 have completed the 3 vaccinations/boosters
45 day baseline -> vaccine -> 4 weeks -> vaccine -> 6 months -> booster

HSV-2 partnering?
Looking for all opportunities, may even look to oncology (cancer) as possible partners

[microphone on mute - discussing easiest question to finish!]

Aims for coming year(s); dura-mater repair, whole vessels (e.g. heart-bypass, AV fistulas, renal patients, delivering stem-cells using Adapt technology.

Signing out; 'thank you and good night!'

;-)